1. Home
  2. ETNB vs IRS Comparison

ETNB vs IRS Comparison

Compare ETNB & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • IRS
  • Stock Information
  • Founded
  • ETNB 2018
  • IRS 1943
  • Country
  • ETNB United States
  • IRS Argentina
  • Employees
  • ETNB N/A
  • IRS N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • IRS Homebuilding
  • Sector
  • ETNB Health Care
  • IRS Real Estate
  • Exchange
  • ETNB Nasdaq
  • IRS Nasdaq
  • Market Cap
  • ETNB 1.0B
  • IRS 873.6M
  • IPO Year
  • ETNB 2019
  • IRS 1994
  • Fundamental
  • Price
  • ETNB $6.06
  • IRS $14.62
  • Analyst Decision
  • ETNB Strong Buy
  • IRS Strong Buy
  • Analyst Count
  • ETNB 10
  • IRS 1
  • Target Price
  • ETNB $27.56
  • IRS $12.62
  • AVG Volume (30 Days)
  • ETNB 2.5M
  • IRS 144.0K
  • Earning Date
  • ETNB 05-08-2025
  • IRS 05-06-2025
  • Dividend Yield
  • ETNB N/A
  • IRS 11.15%
  • EPS Growth
  • ETNB N/A
  • IRS N/A
  • EPS
  • ETNB N/A
  • IRS N/A
  • Revenue
  • ETNB N/A
  • IRS $325,094,048.00
  • Revenue This Year
  • ETNB N/A
  • IRS N/A
  • Revenue Next Year
  • ETNB N/A
  • IRS N/A
  • P/E Ratio
  • ETNB N/A
  • IRS N/A
  • Revenue Growth
  • ETNB N/A
  • IRS N/A
  • 52 Week Low
  • ETNB $4.16
  • IRS $8.21
  • 52 Week High
  • ETNB $11.84
  • IRS $17.67
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 42.57
  • IRS 62.70
  • Support Level
  • ETNB $5.68
  • IRS $13.68
  • Resistance Level
  • ETNB $6.13
  • IRS $14.55
  • Average True Range (ATR)
  • ETNB 0.69
  • IRS 0.96
  • MACD
  • ETNB 0.03
  • IRS 0.24
  • Stochastic Oscillator
  • ETNB 51.62
  • IRS 95.70

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.

Share on Social Networks: